Achilles Therapeutics (ACHL) Competitors $1.48 0.00 (0.00%) As of 03/26/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACHL vs. TERN, CDTX, NVCT, ENGN, ITOS, MNPR, SOPH, DSGN, HUMA, and ANNXShould you be buying Achilles Therapeutics stock or one of its competitors? The main competitors of Achilles Therapeutics include Terns Pharmaceuticals (TERN), Cidara Therapeutics (CDTX), Nuvectis Pharma (NVCT), enGene (ENGN), iTeos Therapeutics (ITOS), Monopar Therapeutics (MNPR), SOPHiA GENETICS (SOPH), Design Therapeutics (DSGN), Humacyte (HUMA), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry. Achilles Therapeutics vs. Terns Pharmaceuticals Cidara Therapeutics Nuvectis Pharma enGene iTeos Therapeutics Monopar Therapeutics SOPHiA GENETICS Design Therapeutics Humacyte Annexon Terns Pharmaceuticals (NASDAQ:TERN) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment. Which has more risk and volatility, TERN or ACHL? Terns Pharmaceuticals has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Does the media prefer TERN or ACHL? In the previous week, Terns Pharmaceuticals had 2 more articles in the media than Achilles Therapeutics. MarketBeat recorded 2 mentions for Terns Pharmaceuticals and 0 mentions for Achilles Therapeutics. Terns Pharmaceuticals' average media sentiment score of 0.00 equaled Achilles Therapeutics'average media sentiment score. Company Overall Sentiment Terns Pharmaceuticals Neutral Achilles Therapeutics Neutral Is TERN or ACHL more profitable? Terns Pharmaceuticals' return on equity of -32.76% beat Achilles Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -32.76% -31.33% Achilles Therapeutics N/A -54.45%-47.68% Which has stronger valuation & earnings, TERN or ACHL? Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns PharmaceuticalsN/AN/A-$90.21M-$1.13-1.86Achilles TherapeuticsN/AN/A-$69.67M-$1.65-0.90 Do analysts prefer TERN or ACHL? Terns Pharmaceuticals presently has a consensus price target of $18.38, indicating a potential upside of 775.00%. Achilles Therapeutics has a consensus price target of $4.00, indicating a potential upside of 170.27%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Terns Pharmaceuticals is more favorable than Achilles Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Achilles Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders and institutionals have more ownership in TERN or ACHL? 98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are owned by institutional investors. 15.1% of Terns Pharmaceuticals shares are owned by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community believe in TERN or ACHL? Terns Pharmaceuticals received 25 more outperform votes than Achilles Therapeutics when rated by MarketBeat users. Likewise, 59.15% of users gave Terns Pharmaceuticals an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote. CompanyUnderperformOutperformTerns PharmaceuticalsOutperform Votes4259.15% Underperform Votes2940.85% Achilles TherapeuticsOutperform Votes1754.84% Underperform Votes1445.16% SummaryTerns Pharmaceuticals beats Achilles Therapeutics on 11 of the 14 factors compared between the two stocks. Remove Ads Get Achilles Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACHL vs. The Competition Export to ExcelMetricAchilles TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.83M$2.83B$5.28B$7.07BDividend YieldN/A1.53%4.87%4.05%P/E Ratio-0.9029.1822.8717.48Price / SalesN/A420.20357.3785.27Price / CashN/A168.6838.1634.64Price / Book0.423.496.233.79Net Income-$69.67M-$72.06M$3.20B$247.10M7 Day PerformanceN/A-12.86%-7.91%-7.31%1 Month Performance8.03%-20.18%-2.94%-10.19%1 Year Performance63.92%-34.28%3.18%-7.40% Achilles Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACHLAchilles Therapeutics2.8211 of 5 stars$1.48flat$4.00+170.3%N/A$60.83MN/A-0.90250TERNTerns Pharmaceuticals3.8567 of 5 stars$2.76-5.5%$18.38+565.8%-61.2%$240.94MN/A-2.3440Gap DownCDTXCidara Therapeutics4.2348 of 5 stars$21.54-3.8%$39.14+81.7%-15.1%$235.93M$1.28M-0.8490Short Interest ↑Gap DownNVCTNuvectis Pharma2.4008 of 5 stars$9.77-6.6%$15.00+53.5%+9.7%$228.54MN/A-8.428Analyst ForecastNews CoverageENGNenGene2.9489 of 5 stars$4.48+4.2%$25.22+463.0%-72.8%$228.38MN/A-7.7231ITOSiTeos Therapeutics2.5577 of 5 stars$5.97-5.5%$25.75+331.3%-56.6%$228.02M$35M-1.9090Gap DownMNPRMonopar Therapeutics2.0353 of 5 stars$36.41-9.7%$44.00+20.8%+977.6%$222.17MN/A-18.4810Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageSOPHSOPHiA GENETICS2.7889 of 5 stars$3.32+1.8%$6.80+104.8%-41.7%$221.40M$65.17M-3.05520Positive NewsDSGNDesign Therapeutics1.2197 of 5 stars$3.86-8.3%$8.00+107.3%-4.9%$219.11MN/A-4.5440Gap DownHUMAHumacyte2.0126 of 5 stars$1.71-13.0%$13.71+704.4%-52.1%$214.59M$1.57M-1.27150Earnings ReportGap DownHigh Trading VolumeANNXAnnexon1.8586 of 5 stars$1.93-14.2%$17.25+793.8%-71.6%$211.74MN/A-1.8460Gap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies TERN Alternatives CDTX Alternatives NVCT Alternatives ENGN Alternatives ITOS Alternatives MNPR Alternatives SOPH Alternatives DSGN Alternatives HUMA Alternatives ANNX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACHL) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achilles Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Achilles Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
